osimertinib
astrazeneca
['osimertinib']
6. #asco23 finds: for stage ib iiia, os hr was 0.49 (p&lt;0.0001), and the 5-year os rate was 88% with osimertinib vs 78% with placebo. we're making a real difference! #worldcancerresearchday #research 
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer